Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Cash: 2019-2025

Historic Change in Cash for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$14.5 million.

  • Allogene Therapeutics' Change in Cash rose 87.84% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.4 million, marking a year-over-year increase of 25.45%. This contributed to the annual value of -$7.9 million for FY2024, which is 137.35% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Change in Cash is -$14.5 million, which was down 246.98% from $9.9 million recorded in Q2 2025.
  • Allogene Therapeutics' Change in Cash's 5-year high stood at $119.6 million during Q2 2024, with a 5-year trough of -$119.4 million in Q3 2024.
  • Moreover, its 3-year median value for Change in Cash was $9.9 million (2025), whereas its average is -$2.2 million.
  • Examining YoY changes over the last 5 years, Allogene Therapeutics' Change in Cash showed a top increase of 288.89% in 2023 and a maximum decrease of 294.36% in 2023.
  • Allogene Therapeutics' Change in Cash (Quarterly) stood at -$15.9 million in 2021, then increased by 21.50% to -$12.5 million in 2022, then soared by 211.69% to $13.9 million in 2023, then soared by 72.40% to $24.0 million in 2024, then soared by 87.84% to -$14.5 million in 2025.
  • Its last three reported values are -$14.5 million in Q3 2025, $9.9 million for Q2 2025, and -$32.8 million during Q1 2025.